Navigation Links
Large-Scale Survey Reveals Low Sexual Desire Most Common Distressing Female Sexual Problem, Affecting Up to One in 10 Women
Date:10/31/2008

nc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.

For more information, please visit http://us.boehringer-ingelheim.com.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Illinois Meth Project Launches Large-Scale Meth Prevention Campaign
2. NIH report on intracranial stent points out need for upcoming large-scale clinical trial
3. Survey reveals disparities in skin cancer knowledge, protection among high school students
4. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Hospitals Could Improve Outcomes for Patients and Save Millions According to Hill-Rom 10th Annual Pressure Ulcer Survey
7. Youth Drug Use at a Five Year Low, New Survey Shows
8. Survey From The Partnership and MetLife Foundation Reveals Important Role Todays Grandparents Play in Teens Lives
9. Parental surveys boost diagnosis abilities of pediatricians
10. National Survey Shows Employee Fears About Consumer-Driven Health Plans on Decline
11. JHA Releases 2007 U.S. Group Disability Mid-Year Market Survey Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 2Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 3Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 4Health News:Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results 5Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 2Health News:JDRF and Lilly partner to fund research to identify beta cell biomarkers 3Health News:Adult Type 2 Diabetes Can Be Predicted in Childhood 2Health News:Blue Cross and Blue Shield of Texas Announces Flexible, Affordable Blue MedicareRx(SM) Medicare Prescription Drug Plans 2Health News:New Gallup Survey Finds Half of Los Angeles Area Residents Have Taken in a Near-Homeless Person, One-Third Fear Homelessness Themselves 2Health News:New Gallup Survey Finds Half of Los Angeles Area Residents Have Taken in a Near-Homeless Person, One-Third Fear Homelessness Themselves 3Health News:Pa. Department of Public Welfare Reminds New Parents About 'Safe Haven' Law 2
Breaking Medicine Technology:Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 2ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 3ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program 4ACCU CHEK 28R 29 Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy com 61955 1ACCU CHEK 28R 29 Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy com 61955 2ACCU CHEK 28R 29 Partners With MYLEstone Health to Enhance iPhone App Glucose Buddy and Web Site glucosebuddy com 61955 3Victory Pharma Inc Announces Launch of NAPRELAN 28R 29 Dose Card 61950 1Victory Pharma Inc Announces Launch of NAPRELAN 28R 29 Dose Card 61950 2Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 1Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 2Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 3Jubilant Organosys UAB and Southern Research Enter Into Drug Discovery Joint Venture 6469 4